Treeline Biosciences Inc. has synthesized new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety covalently linked to transcriptional enhancer factor TEF (TEAD)-targeting moiety potentially useful for the treatment of cancer.